Cancer clinical trials in the region Nouvelle-Aquitaine

391 currently recruiting clinical trials
Region Nouvelle-Aquitaine

Phase 3 Lung cancer #NCT04339218
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Institut Bergonié
Phase 3 Liver and bile duct cancer #NCT05078047
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3 Colon cancer Rectal cancer #NCT05078047
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3 Breast cancer #NCT06312176
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT06216301
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR MET NTRK-1/2/3 RET ROS-1
8 recruiting sites
NovoCure GmbH
Phase 3 Lung cancer #NCT05078047
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3 Breast cancer #NCT06393374
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
17 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Stomach and esophageal cancer #NCT05078047
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3 Pancreas cancer #NCT00268411
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
14 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 3 Stomach and esophageal cancer #NCT06346392
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca